Abstract
Objective
To compare the pharmacokinetics of two dosing regimens of cisapride and their effects on QTc interval.
Design
Thirty-one pre-term infants were enrolled in two neonatal intensive care units. In 16 infants, cisapride was started at 0.2 mg/kg orally every 6 h (group A) and in 15 infants at 0.1 mg/kg orally every 3 h (group B). Electrocardiograms were performed before and after 72 h of treatment to calculate the QTc interval according to the Bazett formula. After 72 h of treatment, cisapride and norcisapride trough concentrations, and concentrations 1 h after the next cisapride administration were quantified in serum. A linear regression analysis was performed to analyse the effect of postnatal and postconception age.
Results
At the start of cisapride treatment, mean postnatal age was 22.9±13.9 days (mean±SD) for group A and 23.3±15.0 days for group B, and mean postconception age was 34.0±1.8 weeks for group A and 33.3±0.8 weeks for group B. The QTc interval increased equally in both groups (group A: +37±20 ms, and group B: + 38±25 ms; P=0.9). Mean concentration of cisapride 1 h after administration was, as expected from the dosing regimen, significantly higher in group A than in group B (123.7±43.2 ng/ml versus 86.7±27.8 ng/ml; P=0.03).The difference in trough concentration was not significant (107.4±44.3 ng/ml versus 78.2±35.4 ng/ml; P=0.09). There was a positive correlation between QTc prolongation and cisapride serum concentration (peak: R2=0.20, P=0.015; trough: R2=0.24, P=0.008) and an inverse correlation between postnatal age and concentration 1 h after administration concentration of cisapride (R2=0.19, P=0.02). No correlation was found for postconception age.
Conclusion
Postnatal age has an inverse relationship with cisapride serum concentration in premature infants, whereas postconception age is not correlated. The maturation process of the biotransformation system of cisapride during the first weeks of life, triggered by birth, but independent of gestational age at birth can explain this observation. The effect of cisapride on cardiac repolarisation is positively related with the cisapride serum concentration. Administering cisapride every 3 h instead of every 6 h could be advantageous, as it is associated with lower peak cisapride serum concentrations. Further investigations are required to confirm this and its potential clinical benefit on QTc and arrhythmia risk.
Similar content being viewed by others
References
Committee on Safety of Medicines/Medicines Control Agency (1998) Cisapride (Prepulsid): risk of arrhythmias. Curr Probl Pharmacovigilance 24:11
Craig JS, Tubman TRJ, McClure BG (1998) Survey of cisapride usage in preterm infants in UK and Ireland. Pediatr Res 44:425
Gheuens J (2000) http://www.janssen.com/cacPro/Pro_Lim_Ac_DDL.htm
Ferriman A (2000) UK licence for cisapriide suspended. BMJ 321:259
Cools F, Benatar A, Bougatef A, Vandenplas Y (2001) The effect of cisapride on the corrected QT interval and QT dispersion in premature infants. J Pediatr Gastroenterol Nutr 33:178–181
Benatar A, Feenstra A, Decraene T, Vandenplas Y (2000) Effects of cisapride on corrected QT interval, heart rate, and rhythm in infants undergoing polysomnography. Pediatrics 106:E85
Benatar A, Feenstra A, Decraene T, Vandenplas Y (2000) Cisapride plasma levels and corrected QT interval in infants undergoing routine polysomnography. J Pediatr Gastroenterol Nutr 33:41–46
Benatar A, Ramet J, Decraene T, Vandenplas Y (2002) QT interval in normal infants during sleep with concurrent evaluation of QT correction formulae. Med Sci Monit 8:351–356
Meulderman W, Van Peer A, Hendrickx J et al (1988) Excretion and biotransformation of cisapride in dogs and humans after oral administration. Drug Metab Dispos 16:403–409
Lacroix D, Sonnier M, Moncion A, Cheron G, Cresteil T (1997) Expression of CYP3A in human liver: evidence that the shift between CYP3A7 and CYP3A4 occurs immediately after birth. Eur J Biochem 247:625–634
Dubin A, Kikkert M, Mirmiran M, Ariagno R (2001) Cisapride associated with QTc prolongation in very low birth weight preterm infants. Pediatrics 107:1313–1316
Drolet B, Khalifa M, Daleau P, Hamelin BA, Turgeon J (1998) Block of the rapid component of the delayed rectifier potassium current by the prokinetic agent cisapride underlies drug-related lengthening of the QT interval. Circulation 97:204–210
Gintant GA, Limberis JT, McDermott JS, Wegner CD, CoxBF (2001) The canine Purkinje fiber: an in vitro model system for acquired long QT syndrome and drug-induced arrhythmogenesis. J Cardiovasc Pharmacol 37:607–618
Preechagoon Y, Charles B, Piotrovskij V, Donovan T, Van Peer A (1999) Population pharmacokinetics of enterally administered cisapride in young infants with gastro-oesophageal reflux disease. J Clin Pharmacol 48:688–693
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Cools, F., Benatar, A., Bruneel, E. et al. A comparison of the pharmacokinetics of two dosing regimens of cisapride and their effects on corrected QT interval in premature infants. Eur J Clin Pharmacol 59, 17–22 (2003). https://doi.org/10.1007/s00228-003-0582-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00228-003-0582-6